cholestyramine resin has been researched along with Hyperlipoproteinemia Type II in 146 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 76 (52.05) | 18.7374 |
| 1990's | 63 (43.15) | 18.2507 |
| 2000's | 5 (3.42) | 29.6817 |
| 2010's | 2 (1.37) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brunt, JNH; Chan, DC; Lewis, B; Pang, J; Watts, GF | 1 |
| Ayed, MB; Benmously, R; Debbiche, A; Fenniche, S; Hammami, H; Marrak, H; Mokhtar, I; Souissi, A | 1 |
| Inazu, A; Ino, H; Kawashiri, MA; Kobayashi, J; Koizumi, J; Mabuchi, H; Nohara, A; Tada, H; Takata, M; Tsuchida, M; Yamagishi, M | 1 |
| Bartuli, A; Gagliardi, MG; Guccione, P; Macchiaiolo, M; Toscano, A | 1 |
| Bang, H; Colindres, RE; Hogan, SL; Kshirsagar, AV; Shoham, DA; Simpson, RJ | 1 |
| Hashemi, MJ; Hekmat, M; Kouhi, A; Mojtahedzadeh, S; Naderi, N; Nobahar, R; Rafeiyian, S | 1 |
| Leonard, JV; Lloyd, JK; West, RJ | 1 |
| Barker, K; Carter, RC; Cassels, E; Jelfs, R; Mann, JI; Simpson, HC | 1 |
| Biso, P; Melchionda, N; Parenti, M; Pasquali, R | 1 |
| Duffield, RG; Jadhav, A; Spengel, FA; Thompson, GR; Wood, CB | 1 |
| Cocuzza, E; Franceschini, G; Gianfranceschi, G; Motanari, G; Sirtori, CR; Sirtori, M | 1 |
| Aldrich, RF; Battaglini, JW; Brensike, JF; Kelsey, SF; Levy, RI; Loh, IK; Moriarty, DJ; Passamani, ER; Richardson, JM; Stone, NJ | 1 |
| Durrington, PN; Miller, JP | 1 |
| Carter, RD; Cobbe, SM; Jones, DB; Lousley, S; Mann, JI; Simpson, HC; Slaughter, P | 1 |
| Mann, JI | 1 |
| de Boer, HH; Hendriks, T; van Niekerk, JL | 1 |
| Matsuzawa, Y; Sudo, H; Yamamoto, A; Yamamura, T; Yokoyama, S | 1 |
| László, A; Simon, N | 1 |
| Glueck, CJ | 1 |
| Farinaro, E; Mancini, M; Montefusco, S; Postiglione, A | 1 |
| Kuo, PT | 1 |
| Aldrich, RF; Battaglini, JW; Brensike, JF; Detre, KM; Epstein, SE; Fisher, MR; Kelsey, SF; Levy, RI; Loh, IK; Moriarty, DJ; Myrianthopoulos, MB; Passamani, ER; Richardson, JM; Stone, NJ | 1 |
| Schade, RW | 1 |
| Betteridge, DJ; Galton, DJ; Krone, W; Middleton, C | 1 |
| Koizumi, J; Mabuchi, H; Sakai, T; Sakai, Y; Takeda, R; Wakasugi, T; Watanabe, A; Yoshimura, A | 1 |
| Widhalm, K | 2 |
| Kane, JP; Malloy, MJ | 1 |
| Havel, RJ; Kane, JP | 2 |
| Myant, NB; Soutar, AK; Thompson, GR | 1 |
| Angelin, B; Björkhem, I; Einarsson, K; Ewerth, S | 1 |
| Miettinen, TA | 2 |
| Neureuther, G; Richter, WO; Schwandt, P; Weisweiler, P | 1 |
| Lehtonen, A; Viikari, J | 1 |
| Lorimer, AR; Morgan, HG; Packard, CJ; Shepherd, J; Stewart, JM | 1 |
| Bicker, S; Lawrie, TD; Morgan, HG; Packard, CJ; Shepherd, J | 1 |
| Olbricht, CJ | 1 |
| Peters, TK | 1 |
| Eliav, O; Friedlander, Y; Leitersdorf, E; Pfister, P; Schurr, D | 1 |
| Eliav, O; Leitersdorf, E; Muratti, EN; Peters, TK | 1 |
| de Bruin, TW; Koomans, HA; Rabelink, TJ; Stroes, ES | 1 |
| Bowler, A; Elsegood, CL; Mamo, JC; Redgrave, TG | 1 |
| Kolesár, P; Kupcová, V; Mojto, V; Raslová, K; Ulicná, O | 1 |
| Davies, G; Kitano, Y; Maher, VM; Matthews, S; Mir, A; Neuwirth, C; Prescott, RJ; Rees, A; Shortt, MB; Thompson, GR | 1 |
| Betteridge, DJ; Cooper, MB; Gasser, JA; Saggerson, ED; Tan, KC | 1 |
| Dann, EJ; Eisenberg, S; Eliav, O; Leitersdorf, E; Meiner, V; Muratti, EN; Peters, TK; Sehayek, E; Stein, Y | 1 |
| Leitersdorf, E; Muratti, EN; Peters, TK | 1 |
| Hodgson, JM; Marks, SJ; Matthews, PG; Myers, KA; Wahlqvist, ML | 1 |
| Angelin, B; Berglund, L; Bondjers, G; Eggertsen, G; Eriksson, M; Lindén, T; Olofsson, SO; Wiklund, O | 1 |
| Bacon, S; Illingworth, DR; Mahley, RW; Schmidt, EB; Weisgraber, KH | 1 |
| Gudnason, V; Humphries, SE; Lloyd, JK; Muller, DP | 1 |
| Kritchevsky, SB; Morris, DL | 1 |
| Knudtzon, J; Ose, L; Refsum, H; Sivertsen, M; Tonstad, S | 1 |
| Wendelhag, I; Wiklund, O; Wikstrand, J | 1 |
| Gørbitz, C; Ose, L; Retterstøl, K; Stugaard, M | 1 |
| Farmer, JA; Gotto, AM | 1 |
| Cheung, J; Crook, MA; Lumb, PJ; Wierzbicki, AS | 1 |
| Ose, L; Refsum, H; Tonstad, S; Ueland, PM | 1 |
| Knight, BL; Patel, DD; Soutar, AK; Sun, XM | 1 |
| Crook, MA; Lumb, PJ; Semra, YK; Wierzbicki, AS | 1 |
| Higashikata, T; Inazu, A; Kajinami, K; Koizumi, J; Mabuchi, H; Yagi, K | 1 |
| Kajinami, K; Koizumi, J; Mabuchi, H | 1 |
| Hoogerbrugge, N | 1 |
| Fukuzawa, S; Inagaki, M; Inoue, T; Morooka, S; Ozawa, S | 1 |
| Bourbon, M; Knight, BL; Naoumova, RP; Neuwirth, CK; O'Neill, FH; Patel, DD; Soutar, AK; Taylor, GW; Thompson, GR | 1 |
| Leijd, B | 1 |
| Casdorph, HR | 1 |
| Ebeling, T; Happonen, P; Miettinen, TA; Pyörälä, K; Turtola, H; Uusitupa, MI; Voutilainen, E | 1 |
| Berg, K; Foss, OP; Hjermann, I; Leren, P; Leren, TP | 1 |
| Lund, H; Norseth, J; Ose, L; Stugaard, M; Wiig, I | 1 |
| Koletzko, B; Kupke, I; Wendel, U | 1 |
| Makino, I | 1 |
| Giovannetti, PM; Wolfe, BM | 1 |
| McCoy, E; Yokoyama, S | 1 |
| Ebeling, T; Pyörälä, K; Reijonen, T; Turtola, H; Uusitupa, M; Voutilainen, E | 1 |
| Betteridge, DJ; Bhatnager, D; Bing, RF; Durrington, PN; Evans, GR; Flax, H; Jay, RH; Lewis-Barned, N; Mann, J; Matthews, DR | 1 |
| Ebeling, T; Happonen, P; Parviainen, M; Pyörälä, K; Turtola, H; Uusitupa, M; Voutilainen, E | 1 |
| Ausina Gómez, A; Dalmau Serra, J; Gilsanz Peral, A; Montero Brens, C | 1 |
| Schlienger, JL | 1 |
| Liu, K | 1 |
| Angelin, B; Berglund, L; Dallner, G; Elmberger, PG; Eriksson, M; Kalén, A; Lund, E; Reihnér, E | 1 |
| Curtis, DM; Driscoll, DJ; Goldman, DH; Weidman, WH | 1 |
| Betteridge, DJ; Jay, RH; Katz, M; McGarrigle, HH; Reckless, JP; Stirling, C; Sturley, RH | 1 |
| Angelin, B; Berglund, L; Bondjers, G; Eriksson, M; Fager, G; Olofsson, SO; Wiklund, O | 1 |
| Gylling, H; Miettinen, TA; Vanhanen, H | 1 |
| Kritchevsky, SB; Morris, DL; Truong, KN; Tyroler, HA; Wilcosky, TC | 1 |
| Erkelens, DW | 1 |
| Bard, JM; Douste-Blazy, P; Fruchart, JC; Parra, HJ | 1 |
| Angelin, B; Berglund, L; Bondjers, G; Eriksson, M; Fager, G; Lindén, T; Olofsson, SO; Sjöberg, A; Wiklund, O | 1 |
| Kurota, M; Maeda, H; Matsuda, T; Miyaho, S; Morikawa, K; Nakai, T; Oida, K; Takahashi, S; Takai, H; Tamai, T | 1 |
| Betteridge, DJ; Jay, RH; Rampling, MW | 1 |
| Aubert, I; Bauduceau, B; Chanu, B; Dachet, C; Emmerich, J; Erlich, D; Gautier, D; Jacotot, B; Rouffy, J | 1 |
| Ast, M; Frishman, WH | 1 |
| Escobar Gallego, A; Fernández Gómez, E; García Alegría, JJ; Gascón Luna, F; Masana Marín, L; Mongil Ruiz, I; Obando Santaella, I | 1 |
| Chistiakova, AM; Frolova, IuV; Khanefel'd, M; Leonkhardt, V; Lozovskiĭ, VT; Remezova, OV; Ryzhenkov, VE; Solov'eva, MA; Triufanov, VF; Vasil'eva, LE | 1 |
| Burrichter, H; Geisel, J; Oette, K | 1 |
| Angelin, B; Einarsson, K; Hultcrantz, R; Leijd, B | 1 |
| Cattin, L; Da Col, PG; Fonda, M; Mazzone, C; Pertot, P | 1 |
| Demacker, PN; Mol, MJ; Stalenhoef, AF; Stuyt, PM | 1 |
| Bascoul, J; Crastes de Paulet, A; Domergue, N; Gozé, C | 1 |
| Bedford, DK; Gaw, A; Kilday, C; Lorimer, AR; Packard, CJ; Series, JJ; Shepherd, J | 1 |
| Kreisberg, R; Mantell, G; Miller, V; Shapiro, DR; Stein, E; Washington, L | 1 |
| Löbel, P; Schrör, K; Steinhagen-Thiessen, E | 1 |
| Jones, PH | 1 |
| Ishii, K; Kawai, C; Kita, T; Kume, N; Mikami, A; Nagano, Y; Yokode, M | 1 |
| Reynolds, GA | 1 |
| Cuthbert, JA; East, CA; Lipsky, PE | 1 |
| Kuusisto, P; Manninen, V; Neuvonen, PJ; Vapaatalo, H | 1 |
| Bost, M; Boucherle, A; Calop, J; Rossignol, AM | 1 |
| Mol, MJ; Stalenhoef, AF; Stuyt, PM | 1 |
| Illingworth, DR; Pappu, AS | 1 |
| Cramb, R; Hughes, EA; Jones, AF | 1 |
| Aubert, I; Besseau, M; Chanu, B; Charpak, Y; Dachet, C; Emmerich, J; Herlich, D; Jacotot, B; Rouffy, J | 1 |
| Havel, RJ | 1 |
| Betteridge, J; Curtis, LD; Dickson, AC; Ling, KL | 1 |
| Berg, K; Foss, OP; Hjermann, I; Leren, P; Leren, TP; Viksmoen, L | 1 |
| Angelin, B; Einarsson, K; Eriksson, M | 1 |
| Houlston, R; Lewis, B; Quiney, J; Watts, GF | 1 |
| Baggen, MG; Erkelens, DW; Kettner, M; Koningsberger, JC; Mol, MJ; Van Doormaal, JJ | 1 |
| Fears, R; Ferres, H; Haacke, H; Mäder, C; Parwaresch, MR | 1 |
| de Wit, E; Gevers Leuven, JA; Havekes, L; Kempen, HJ; vd Voort, H | 1 |
| Stein, EA | 1 |
| Davignon, J | 1 |
| Breslow, JL; Eisenberg, S; Weintraub, MS | 1 |
| Nikkilä, EA; Tikkanen, MJ | 1 |
| Gotto, AM; Jones, PH; Scott, LW | 1 |
| Dine, M; Glueck, CJ; Laskarzewski, P; Mellies, MJ; Perry, T | 1 |
| Brewer, HB; Hoeg, JM; Starzl, TE | 1 |
| Angelin, B; Berglund, L; Eriksson, M; Lantz, B | 1 |
| Ford, J; Jenkinson, M; Thompson, GR; Trayner, I | 1 |
| Bailey, KR; Brewer, HB; Hoeg, JM; Maher, MB | 1 |
| Proniv, LN; Vygovskiĭ, VP | 1 |
| Funahashi, T; Kishino, B; Matsuzawa, Y; Yamamoto, A; Yamamura, T; Yokoyama, S | 1 |
| Bonfiglioli, D; Branchi, A; Cabrini, E; Pogliaghi, I; Sommariva, D; Tirrito, M | 1 |
| Delcroix, C; Lontie, JF; Malmendier, CL | 1 |
| Brewer, HB; Gregg, RE; Hoeg, JM; Lakatos, E; Schaefer, EJ; Sprecher, DL; Zech, LA | 1 |
| Levy, RI; Schaefer, EJ | 1 |
| Bailey, KR; Brewer, HB; Gregg, RE; Hoeg, JM; Maher, MB; Sprecher, DL; Zech, LA | 1 |
| Aldrich, RF; Brensike, JF; Detre, KM; Epstein, SE; Kelsey, SF; Levy, RI; Loh, IK; Passamani, ER; Richardson, JM; Stone, NJ | 1 |
| Gibson, P; Lloyd, J; West, R | 1 |
| Adolph, R; Glueck, CJ; Rice, V; Spitz, HB; Stein, EA | 1 |
| Bloch, CA; Botha, A; McNamara, DJ; Mendelsohn, D | 1 |
| Demant, T; Hailer, S; Keller, C; Wolfram, G; Zöllner, N | 1 |
13 review(s) available for cholestyramine resin and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Clinical aspects of hyperlipidaemia.
Topics: Adult; Child; Cholestyramine Resin; Chylomicrons; Coronary Disease; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Lipoproteins; Lipoproteins, HDL; Xanthomatosis | 1984 |
[Hyperlipoproteinemia type II].
Topics: Adolescent; Adult; Cecum; Child; Cholesterol, Dietary; Cholestyramine Resin; Clofibrate; Coronary Disease; Dextrothyroxine; Diet; Drug Therapy, Combination; Humans; Hyperlipoproteinemia Type II; Ileum; Lipoproteins, LDL; Neomycin; Nicotinic Acids; Plasmapheresis; Portacaval Shunt, Surgical; Xanthogranuloma, Juvenile | 1980 |
Treatment of hypercholesterolemia.
Topics: Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Heterozygote; Homozygote; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Neomycin; Niacin; Nicotinic Acids; Probucol; Sitosterols; Thyroxine | 1982 |
Therapy of hyperlipidemic states.
Topics: Cholesterol, Dietary; Cholestyramine Resin; Clofibrate; Colestipol; Dietary Fats; Drug Therapy, Combination; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Lipoproteins, LDL; Lipoproteins, VLDL; Niacin; Nicotinic Acids; Sitosterols | 1982 |
Choosing the right lipid-regulating agent. A guide to selection.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Niacin; Triglycerides | 1996 |
[Study of LDL receptors and response to lovastatin therapy in familial homozygotic hypercholesterolemia].
Topics: Cholestyramine Resin; Drug Therapy, Combination; Homozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Receptors, LDL | 1991 |
[Advance in drug treatment of primary and familial hypercholesterolemia].
Topics: Animals; Cholestyramine Resin; Drugs, Chinese Herbal; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Panax; Plants, Medicinal; Probucol | 1991 |
Bile acid sequestrants.
Topics: Chemical Phenomena; Chemistry; Child; Child, Preschool; Cholestyramine Resin; Colestipol; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lipoproteins, VLDL; Polyamines; Resins, Plant | 1990 |
Efficacy and tolerability of simvastatin (MK-733).
Topics: Adrenal Cortex; Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin | 1989 |
Functional activities of hepatic lipoprotein receptors.
Topics: Animals; Binding Sites; Cholesterol, Dietary; Cholestyramine Resin; Chylomicrons; Dogs; Endocytosis; Estradiol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Liver; Mutation; Rabbits; Rats; Receptors, Cell Surface; Receptors, LDL; Receptors, Lipoprotein | 1986 |
Treatment of hypercholesterolemia.
Topics: Animals; Cholestyramine Resin; Clofibrate; Colestipol; Cricetinae; Dogs; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Mice; Middle Aged; Neomycin; Niacin; Pentanoic Acids; Pregnancy; Probucol; Rats | 1986 |
The diagnosis and management of hyperlipidemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibrate; Colestipol; Coronary Disease; Dextrothyroxine; Dietary Fats; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Lipoproteins; Lipoproteins, LDL; Neomycin; Niacin; Pentanoic Acids; Probucol; Receptors, LDL; Triglycerides | 1986 |
Pathogenesis and management of lipoprotein disorders.
Topics: Abetalipoproteinemia; Adolescent; Adult; Aged; Child; Child, Preschool; Cholestyramine Resin; Chylomicrons; Colestipol; Dietary Fats; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Hyperlipoproteinemias; Hypobetalipoproteinemias; Hypolipoproteinemias; Infant; Infant, Newborn; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Niacin; Pentanoic Acids; Probucol; Tangier Disease | 1985 |
46 trial(s) available for cholestyramine resin and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resin.
Topics: Adult; Aged; Angiography; Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Coronary Artery Disease; Data Interpretation, Statistical; Diet; Disease Progression; Humans; Hyperlipoproteinemia Type II; Incidence; Male; Middle Aged; Phenotype; Severity of Illness Index; Treatment Outcome | 2016 |
The effect of cholesterol reduction with cholestyramine on renal function.
Topics: Adult; Anticholesteremic Agents; Cholesterol, Dietary; Cholestyramine Resin; Combined Modality Therapy; Coronary Disease; Diet, Fat-Restricted; Double-Blind Method; Glomerular Filtration Rate; Humans; Hyperlipoproteinemia Type II; Kidney; Male; Middle Aged; Risk Factors; Treatment Failure | 2005 |
Microporous cholestyramine in suspension form.
Topics: Cholestyramine Resin; Clinical Trials as Topic; Constipation; Double-Blind Method; Humans; Hyperlipoproteinemia Type II; Random Allocation; Suspensions | 1982 |
Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study.
Topics: Adult; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged | 1984 |
A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolaemia.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cholestyramine Resin; Clinical Trials as Topic; Dietary Fats; Humans; Hyperlipoproteinemia Type II; Lipoproteins, VLDL; Middle Aged; Phenols; Probucol; Triglycerides | 1984 |
National Heart, Lung, and Blood Institute type II Coronary Intervention Study: design, methods, and baseline characteristics.
Topics: Adult; Angiography; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Female; Follow-Up Studies; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Male; Middle Aged; National Institutes of Health (U.S.); Random Allocation; Research Design; United States | 1982 |
Regulation of sterol synthesis in human intestinal mucosa.
Topics: Administration, Oral; Adolescent; Adult; Chenodeoxycholic Acid; Cholesterol, Dietary; Cholestyramine Resin; Fasting; Female; Humans; Hyperlipoproteinemia Type II; Intestinal Mucosa; Jejunum; Sterols | 1980 |
Pre-entry characteristics of participants in the Lipid Research Clinics' Coronary Primary Prevention Trial.
Topics: Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Humans; Hyperlipoproteinemia Type II; Lipids; Random Allocation | 1983 |
Fluvastatin in severe hypercholesterolemia: analysis of a clinical trial database.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Indoles; Information Systems; Longitudinal Studies; Male; Middle Aged; Placebos; Risk Factors; Triglycerides | 1995 |
High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Delayed-Action Preparations; Drug Combinations; Fatty Acids, Monounsaturated; Fluvastatin; Heterozygote; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Kidney; Liver; Longitudinal Studies; Placebos; Safety; Triglycerides | 1995 |
Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Coronary Artery Disease; Creatine Kinase; Drug Combinations; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Kidney; Liver; Male; Middle Aged; Patient Compliance; Placebos; Safety; Triglycerides | 1995 |
Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis.
Topics: Adult; Blood Component Removal; Cholestyramine Resin; Colestipol; Coronary Angiography; Coronary Artery Disease; Data Interpretation, Statistical; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Lipoprotein(a); Lipoproteins, LDL; Lovastatin; Middle Aged; Odds Ratio; Simvastatin | 1995 |
Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Double-Blind Method; Drug Combinations; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heterozygote; Humans; Hyperlipoproteinemia Type II; Indoles; Male; Middle Aged; Myositis; Placebos; Safety; Single-Blind Method; Triglycerides | 1994 |
Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Bezafibrate; Cholestyramine Resin; Cohort Studies; Double-Blind Method; Drug Therapy, Combination; Drug Tolerance; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lipids; Lipoproteins; Male; Middle Aged; Retrospective Studies; Time Factors | 1994 |
Apolipoprotein E phenotypes in familial hypercholesterolaemia: importance for expression of disease and response to therapy.
Topics: Apolipoproteins E; Cholestyramine Resin; Double-Blind Method; Humans; Hyperlipoproteinemia Type II; Lipids; Phenotype; Pravastatin; Treatment Outcome | 1993 |
Changes in dietary fat intake preceding the diagnosis of cancer.
Topics: Adult; Bias; Cholestyramine Resin; Coronary Disease; Dietary Fats; Energy Intake; Follow-Up Studies; Humans; Hyperlipoproteinemia Type II; Male; Mental Recall; Middle Aged; Neoplasms; Tennessee | 1995 |
Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Child; Cholestyramine Resin; Double-Blind Method; Energy Intake; Female; Growth; Homocysteine; Humans; Hyperlipoproteinemia Type II; Male | 1996 |
Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Middle Aged; Simvastatin; Triglycerides | 1997 |
The C677T mutation in the methylenetetrahydrofolate reductase gene predisposes to hyperhomocysteinemia in children with familial hypercholesterolemia treated with cholestyramine.
Topics: Anticholesteremic Agents; Child; Cholestyramine Resin; Female; Folic Acid; Genotype; Heterozygote; Homocysteine; Homozygote; Humans; Hyperlipoproteinemia Type II; Male; Methylenetetrahydrofolate Reductase (NADPH2); Mutation; Oxidoreductases Acting on CH-NH Group Donors | 1998 |
Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. The Familial Hypercholesterolaemia Regression Study Group.
Topics: Adult; Anticholesteremic Agents; Cholestyramine Resin; Colestipol; Female; Genotype; Heterozygote; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Phenotype; Receptors, LDL; Simvastatin | 1998 |
High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Drug Administration Schedule; Drug Combinations; Fenofibrate; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 1998 |
Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestenones; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipoproteinemia Type II; Male; Mevalonic Acid; Middle Aged; Mutation; Pyrroles; Receptors, LDL; RNA, Messenger | 2001 |
Effects of neomycin alone and in combination with cholestyramine on serum cholesterol and fecal steroids in hypercholesterolemic subjects.
Topics: Adult; Bile Acids and Salts; Cholesterol; Cholestyramine Resin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Feces; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Middle Aged; Neomycin; Sitosterols | 1979 |
Lathosterol and other noncholesterol sterols during treatment of hypercholesterolemia with lovastatin alone and with cholestyramine or guar gum.
Topics: Adult; Cholesterol; Cholestyramine Resin; Dietary Fiber; Female; Galactans; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Male; Mannans; Middle Aged; Plant Gums; Sterols | 1992 |
[Familial hypercholesterolemia--intensive diet therapy combined with drug therapy].
Topics: Adolescent; Adult; Aged; Cholestyramine Resin; Drug Evaluation; Drug Therapy, Combination; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Middle Aged | 1992 |
High protein diet complements resin therapy of familial hypercholesterolemia.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Dietary Carbohydrates; Dietary Proteins; Energy Intake; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins, VLDL; Male; Middle Aged; Triglycerides | 1992 |
Comparison between lovastatin and cholestyramine in the treatment of moderate to severe primary hypercholesterolaemia.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Triglycerides | 1992 |
Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine.
Topics: Adolescent; Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pravastatin; Treatment Outcome; Triglycerides | 1992 |
Combination therapy with lovastatin and guar gum versus lovastatin and cholestyramine in treatment of hypercholesterolemia.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Blood Pressure; Body Weight; Cholestyramine Resin; Double-Blind Method; Drug Therapy, Combination; Female; Galactans; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Mannans; Middle Aged; Plant Gums | 1991 |
Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia.
Topics: Adrenal Glands; Cholestyramine Resin; Female; Gonadal Steroid Hormones; Gonadotropins, Pituitary; Gonads; Humans; Hydrocortisone; Hyperlipoproteinemia Type II; Male; Pravastatin; Sex Hormone-Binding Globulin; Steroids | 1991 |
Changes in plasma lipid and lipoprotein cholesterol and weight prior to the diagnosis of cancer.
Topics: Adult; Biomarkers, Tumor; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Follow-Up Studies; Humans; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Neoplasms; Precancerous Conditions; Smoking | 1991 |
Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels.
Topics: Adult; Aged; Alanine Transaminase; Anticholesteremic Agents; Apolipoproteins; Aspartate Aminotransferases; Cholesterol, LDL; Cholestyramine Resin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Naphthalenes; Pravastatin; Randomized Controlled Trials as Topic; Triglycerides | 1990 |
Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment.
Topics: Adult; Anticholesteremic Agents; Blood Viscosity; Cholestyramine Resin; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Fibrinogen; Hematocrit; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Middle Aged; Naphthalenes; Pravastatin; Rheology | 1990 |
Efficacy and safety of simvastatin (alone or in association with cholestyramine). A 1-year study in 66 patients with type II hyperlipoproteinaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apoproteins; Cholestyramine Resin; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cholestyramine Resin; Double-Blind Method; Drug Therapy, Combination; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Lipoproteins; Patient Compliance; Pyrazines; Triglycerides | 1990 |
Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I.
Topics: Adult; Alanine Transaminase; Anticholesteremic Agents; Cataract; Cholesterol; Cholestyramine Resin; Creatine Kinase; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 1990 |
Activated charcoal in the treatment of hypercholesterolaemia: dose-response relationships and comparison with cholestyramine.
Topics: Adult; Charcoal; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Triglycerides | 1989 |
[Effects of simvastatin on plasma lipids, lipoproteins and apoproteins (A1 and B). 24 cases of major primary hypercholesterolemia].
Topics: Adult; Anticholesteremic Agents; Apoproteins; Cholestyramine Resin; Clinical Trials as Topic; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Random Allocation; Simvastatin | 1988 |
Combination treatment with cholestyramine and bezafibrate for heterozygous familial hypercholesterolaemia.
Topics: Adult; Bezafibrate; Cholestyramine Resin; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Random Allocation | 1988 |
Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia.
Topics: Adult; Apolipoproteins; Cholestyramine Resin; Clinical Trials as Topic; Drug Therapy, Combination; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged | 1988 |
Clinical experience with simvastatin compared with cholestyramine.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1988 |
Decrease in LDL and increase in HDL concentrations in type II hyperlipoproteinaemic patients on low-dose combination therapy of cholestyramine and Complamin.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cholestyramine Resin; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hyperlipoproteinemia Type II; Lipoproteins, VLDL; Male; Middle Aged; Theophylline; Xanthinol Niacinate | 1988 |
The effect of cyclandelate on cholesterol metabolism in patients with familial hypercholesterolaemia.
Topics: Adult; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Cyclandelate; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Lanosterol; Lipoproteins; Male; Mandelic Acids; Middle Aged; Random Allocation | 1987 |
Effects of combination cholestyramine-neomycin treatment on plasma lipoprotein concentrations in type II hyperlipoproteinemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Constipation; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Male; Neomycin; Time Factors | 1985 |
Secondary prevention and lipid lowering: results and implications.
Topics: Angiocardiography; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Diet; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Male; National Institutes of Health (U.S.); Random Allocation; United States | 1985 |
87 other study(ies) available for cholestyramine resin and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
[Tuberous xanthomas as the first manifestation of homozygous familial hypercholesterolaemia].
Topics: Anticholesteremic Agents; Child, Preschool; Cholestyramine Resin; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Skin; Skin Diseases; Xanthomatosis | 2008 |
Marked aortic valve stenosis progression after receiving long-term aggressive cholesterol-lowering therapy using low-density lipoprotein apheresis in a patient with familial hypercholesterolemia.
Topics: Angina Pectoris; Anticholesteremic Agents; Aortic Valve Stenosis; Blood Component Removal; Cholesterol; Cholestyramine Resin; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Disease Progression; Echocardiography; Female; Heart Valve Prosthesis Implantation; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Middle Aged; Secondary Prevention | 2009 |
Homozygous familial hypercholesterolaemia.
Topics: Anticholesteremic Agents; Blood Component Removal; Child, Preschool; Cholestyramine Resin; Coronary Angiography; Coronary Occlusion; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Xanthogranuloma, Juvenile | 2012 |
Supravalvular and valvular aortic stenosis in heterozygous familial hypercholesterolemia.
Topics: Adolescent; Aortic Stenosis, Supravalvular; Aortic Valve Stenosis; Atorvastatin; Cholestyramine Resin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Niacin; Pyrroles | 2007 |
Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Female; Follow-Up Studies; Heterozygote; Humans; Hyperlipoproteinemia Type II; Infant; Lipoproteins, LDL; Male; Patient Compliance; Time Factors | 1980 |
Probucol in patients resistant to the lipid-lowering effects of cholestyramine.
Topics: Adult; Cholestyramine Resin; Humans; Hyperlipoproteinemia Type II; Middle Aged; Phenols; Probucol | 1981 |
Combined effects of probucol and cholestyramine in familial type II hyperlipoproteinaemia.
Topics: Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Phenols; Probucol | 1981 |
Superiority of partial ileal bypass over cholestyramine reducing cholesterol in familial hypercholesterolaemia.
Topics: Adult; Bile Acids and Salts; Body Weight; Cholestyramine Resin; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Ileum; Lipoproteins, LDL; Liver; Male; Middle Aged; Receptors, Drug | 1981 |
Familial hypercholesterolaemia: renewed interest in an old problem.
Topics: Cholestyramine Resin; Humans; Hyperlipoproteinemia Type II | 1984 |
Bile acid drainage by partial small bowel bypass or cholestyramine. Effects on serum cholesterol in Watanabe heritable hyperlipidemic rabbits.
Topics: Animals; Bile Acids and Salts; Cholesterol; Cholestyramine Resin; Colon; Disease Models, Animal; Drainage; Female; Hyperlipoproteinemia Type II; Ileum; Rabbits | 1984 |
Combined drug therapy--cholestyramine and compactin--for familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Drug Therapy, Combination; Female; Heterozygote; Homozygote; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Naphthalenes | 1984 |
[Hyperlipoproteinemia due to congenital bile duct atresia with unusually located tuberous xanthoma].
Topics: Bile Ducts; Bilirubin; Cholesterol; Cholestyramine Resin; Female; Heart Septal Defects; Humans; Hyperlipoproteinemia Type II; Infant; Lipids; Skin; Xanthomatosis | 1983 |
Therapy of familial and acquired hyperlipoproteinemia in children and adolescents.
Topics: Adolescent; Child; Child, Preschool; Cholesterol; Cholesterol, Dietary; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Combined Modality Therapy; Coronary Disease; Energy Intake; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Infant; Infant Food; Lipoproteins, LDL; Male; Patient Compliance; Triglycerides | 1983 |
Diet, drugs, and plasma exchange in the treatment of hyperlipidemia in childhood.
Topics: Adolescent; Child; Child, Preschool; Cholesterol, Dietary; Cholestyramine Resin; Colestipol; Combined Modality Therapy; Coronary Disease; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Plasma Exchange; Polyamines | 1983 |
Treating hyperlipidemia to provide salutary effect on coronary artery disease.
Topics: Arteriosclerosis; Cholestyramine Resin; Colestipol; Coronary Disease; Dietary Fats; Enzyme Inhibitors; Fatty Acids, Unsaturated; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Lipoproteins, LDL | 1984 |
Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Drug Evaluation; Drug Therapy, Combination; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Phospholipids; Triglycerides | 1983 |
Serum lipoproteins during childhood: normal concentrations and primary hyperlipoproteinemias.
Topics: Child; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cholestyramine Resin; Diet; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL | 1982 |
The metabolism of very low density and intermediate density lipoproteins in patients with familial hypercholesterolaemia.
Topics: Adolescent; Adult; Apolipoproteins; Apolipoproteins B; Cholestyramine Resin; Humans; Hyperlipoproteinemia Type II; Ileum; Iodine Radioisotopes; Lipoproteins; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged | 1982 |
Cholestyramine treatment reduces postprandial but not fasting serum bile acid levels in humans.
Topics: Bile Acids and Salts; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Eating; Fasting; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Liver Circulation | 1982 |
Effects of neomycin alone and in combination with cholestyramine on serum methyl sterols and conversion of acetate and mevalonate to cholesterol.
Topics: Acetates; Cholesterol; Cholestyramine Resin; Feces; Humans; Hyperlipoproteinemia Type II; Mevalonic Acid; Neomycin; Steroids; Sterols | 1982 |
Cholestyramine plus pectin in treatment of patients with familial hypercholesterolemia.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pectins | 1982 |
[Diagnosis, clinical features and treatment of hyperlipidemias in children].
Topics: Adolescent; Arteriosclerosis; Child; Cholestyramine Resin; Humans; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Lipoproteins; Risk | 1982 |
Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.
Topics: Adult; Aspartate Aminotransferases; Cholesterol; Cholestyramine Resin; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Middle Aged; Propionates; Triglycerides | 1982 |
Combined drug therapy for familial hypercholesterolemia.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Male; Middle Aged; Nicotinic Acids; Triglycerides | 1980 |
Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism.
Topics: Adult; Aged; Cholesterol; Cholestyramine Resin; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Middle Aged; Receptors, Drug | 1980 |
Low-density-lipoprotein apheresis.
Topics: Anticholesteremic Agents; Blood Component Removal; Cholestyramine Resin; Colestipol; Combined Modality Therapy; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Simvastatin | 1995 |
Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication.
Topics: Adult; Arginine; Blood Pressure; Cholesterol; Cholestyramine Resin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Forearm; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Infusions, Intravenous; Lovastatin; Male; Nitroprusside; omega-N-Methylarginine; Regional Blood Flow; Serotonin; Simvastatin; Vasodilation | 1995 |
Clearance of chylomicron-like lipid emulsions is increased in normal rabbits but not in heterozygous Watanabe heritable hyperlipidaemic rabbits following treatment with cholestyramine or pravastatin.
Topics: Analysis of Variance; Animals; Bile Acids and Salts; Cholestyramine Resin; Chylomicrons; Fat Emulsions, Intravenous; Heterozygote; Hydroxymethylglutaryl CoA Reductases; Hyperlipoproteinemia Type II; Metabolic Clearance Rate; Pravastatin; Rabbits | 1994 |
[Biochemical and functional study of the liver during treatment of familial hyperlipoproteinemia with Mevacor (lovastatin) and Vasosan S (cholestyramine)].
Topics: Cholestyramine Resin; Female; Humans; Hyperlipoproteinemia Type II; Liver; Lovastatin; Male; Middle Aged | 1994 |
Decreased sensitivity to adenosine in platelets from patients with familial hypercholesterolaemia--a change reversed by cholestyramine treatment.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Adult; Cholestyramine Resin; Colforsin; Cyclic AMP; Epoprostenol; Female; Humans; Hyperlipoproteinemia Type II; Male; Platelet Aggregation Inhibitors | 1993 |
Improvement in arterial stiffness during hypolipidaemic therapy is offset by weight gain.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Arteries; Blood Pressure; Body Mass Index; Carotid Artery, Common; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Dietary Fats; Female; Femoral Artery; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Niacin; Simvastatin; Triglycerides; Ultrasonography; Weight Gain | 1993 |
Hypocholesterolemic effects of cholestyramine and colestipol in patients with familial defective apolipoprotein B-100.
Topics: Adult; Aged; Apolipoprotein B-100; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Triglycerides | 1993 |
Response to drugs and diet in a compound heterozygote for familial hypercholesterolaemia.
Topics: Base Sequence; Blotting, Southern; Child; Cholestyramine Resin; Combined Modality Therapy; Diet, Fat-Restricted; Dietary Fats; Drug Therapy, Combination; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Molecular Sequence Data; Mutation; Pedigree; Receptors, LDL; Simvastatin | 1995 |
Intima-media thickness after cholesterol lowering in familial hypercholesterolemia. A three-year ultrasound study of common carotid and femoral arteries.
Topics: Anticholesteremic Agents; Carotid Artery, Common; Cholesterol; Cholestyramine Resin; Female; Femoral Artery; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Tunica Intima; Tunica Media; Ultrasonography | 1995 |
Results of intensive long-term treatment of familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atrial Natriuretic Factor; Cholesterol; Cholestyramine Resin; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Probucol; Quality of Life; Treatment Outcome | 1996 |
Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia.
Topics: Adult; Aged; Anion Exchange Resins; Anticholesteremic Agents; Bile; Cholestyramine Resin; Drug Therapy, Combination; Female; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pravastatin; Receptors, LDL; Treatment Outcome | 1998 |
Clinical efficacy and safety of cerivastatin in the treatment of heterozygous familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Female; Follow-Up Studies; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyridines; Safety; Treatment Outcome; Triglycerides | 1998 |
Secondary prevention with lipid lowering therapy in familial hypercholesterolemia: a correlation between new evolution of stenotic lesion and achieved cholesterol levels after revascularization procedures.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholestyramine Resin; Coronary Artery Bypass; Coronary Artery Disease; Coronary Disease; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Probucol | 1999 |
Metabolism of plasma and biliary lipids in hyperlipoproteinaemia.
Topics: Bile Acids and Salts; Cholesterol; Cholestyramine Resin; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hyperlipoproteinemias; Lipid Metabolism; Lipids; Lipoproteins; Nicotinic Acids; Obesity; Triglycerides | 1979 |
The single dose method of administering cholestyramine.
Topics: Cholesterol; Cholestyramine Resin; Humans; Hyperlipoproteinemia Type II; Longitudinal Studies; Triglycerides | 1975 |
Long-term effect of lovastatin alone and in combination with cholestyramine on lipoprotein (a) level in familial hypercholesterolemic subjects.
Topics: Adolescent; Adult; Aged; Apolipoproteins; Cholestyramine Resin; Drug Therapy, Combination; Female; Follow-Up Studies; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoprotein(a); Lipoproteins; Lovastatin; Male; Middle Aged; Time Factors | 1992 |
Treatment of hypercholesterolemia in children and adolescents.
Topics: Adolescent; Age Factors; Ambulatory Care; Child; Cholesterol, LDL; Cholestyramine Resin; Feasibility Studies; Female; Humans; Hyperlipoproteinemia Type II; Male | 1992 |
[Diagnosis and treatment of familial hypercholesterolemia].
Topics: Adult; Blood Component Removal; Cholesterol, LDL; Cholestyramine Resin; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Probucol; Reference Standards | 1992 |
Long-term treatment of a homozygous cholesteryl ester storage disease with combined cholestyramine and lovastatin.
Topics: Child, Preschool; Cholesterol Esters; Cholestyramine Resin; Homozygote; Humans; Hyperlipoproteinemia Type II; Lipid Metabolism, Inborn Errors; Lovastatin; Male | 1992 |
[Evaluation of the addition of fenofibrate to the simvastatin-cholestyramine combination].
Topics: Anticholesteremic Agents; Cholestyramine Resin; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Lovastatin; Simvastatin | 1991 |
Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia.
Topics: Adult; Aged; Cholesterol; Cholestyramine Resin; Dolichols; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Mevalonic Acid; Middle Aged; Pravastatin; Ubiquinone | 1991 |
Loss of dental enamel in a patient taking cholestyramine.
Topics: Bone Density; Child; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Dental Enamel; Drinking; Humans; Hydrogen-Ion Concentration; Hyperlipoproteinemia Type II; Male; Radiography; Triglycerides | 1991 |
Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins A; Cholestyramine Resin; Coronary Disease; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Naphthalenes; Pravastatin; Receptors, LDL | 1990 |
Hypolipidemic effect and mechanism of ketoconazole without and with cholestyramine in familial hypercholesterolemia.
Topics: Adult; Cholesterol; Cholestyramine Resin; Desmosterol; Drug Therapy, Combination; Feces; Female; Humans; Hyperlipoproteinemia Type II; Intestinal Absorption; Ketoconazole; Lanosterol; Lipids; Lipoproteins; Middle Aged; Squalene | 1991 |
Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia.
Topics: Cholestyramine Resin; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Niacin; Simvastatin | 1990 |
Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Apolipoproteins C; Apolipoproteins E; Bile Acids and Salts; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cholestyramine Resin; Drug Evaluation; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Naphthalenes; Pravastatin; Random Allocation; Triglycerides | 1990 |
[A case of familial hypercholesterolemia associated with nephrotic syndrome].
Topics: Cholestyramine Resin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Middle Aged; Naphthalenes; Nephrotic Syndrome; Pravastatin; Prednisolone; Probucol | 1990 |
[Homozygous familial hypercholesterolemia. Response to combined cholestyramine and lovastatin therapy].
Topics: Child, Preschool; Cholestyramine Resin; Drug Therapy, Combination; Homozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male | 1990 |
[Experimental and clinical study of Vasosan P, a new form of pectin-enriched cholestyramine].
Topics: Animals; Cholesterol; Cholestyramine Resin; Guinea Pigs; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipid Metabolism; Lipids; Lipoproteins, VLDL; Liver; Rats; Triglycerides | 1990 |
[HMG-CoA reductase inhibitors in familial hypercholesterolemia. Therapy with simvastatin alone and in combination with cholestyramine in low dosage; a report of 2 years experiences].
Topics: Adult; Anticholesteremic Agents; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
Increased turnover of very low density lipoprotein triglyceride during treatment with cholestyramine in familial hypercholesterolaemia.
Topics: Adult; Cholestyramine Resin; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipoproteins, VLDL; Male; Middle Aged; Particle Size; Time Factors; Triglycerides | 1990 |
[Effects of low-dose cholestyramine in long-term therapy of hypercholesterolemia].
Topics: Adolescent; Adult; Aged; Cholesterol, HDL; Cholestyramine Resin; Drug Evaluation; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Middle Aged; Time Factors | 1990 |
The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia.
Topics: Adult; Apolipoproteins; Cholesterol; Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1990 |
Serum level of 7 alpha-hydroxycholesterol in hypercholesterolemic patients treated with cholestyramine.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholestyramine Resin; Humans; Hydroxycholesterols; Hyperlipoproteinemia Type II; Kinetics; Lipoproteins, LDL; Middle Aged | 1990 |
Cholestyramine treatment of type IIa hypercholesterolaemia normalizes platelet reactivity against prostacyclin.
Topics: Blood Platelets; Cardiovascular Agents; Cholestyramine Resin; Epoprostenol; Humans; Hyperlipoproteinemia Type II; Iloprost; Male; Platelet Aggregation; Thromboxane B2 | 1988 |
The use of combined LDL affinity apheresis utilizing dextran sulfate cellulose columns and hypolipidemic medications in patients with severe hypercholesterolemia to assess regression of atherosclerosis.
Topics: Adult; Anticholesteremic Agents; Arteriosclerosis; Blood Component Removal; Cellulose; Cholesterol, LDL; Cholestyramine Resin; Combined Modality Therapy; Dextran Sulfate; Dextrans; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Male; Plasmapheresis; Remission Induction | 1988 |
Induction of mRNA for low-density lipoprotein receptors in heterozygous Watanabe heritable hyperlipidemic rabbits treated with CS-514 (Pravastatin) and cholestyramine.
Topics: Animals; Anticholesteremic Agents; Cholestyramine Resin; Heptanoic Acids; Heterozygote; Hyperlipoproteinemia Type II; Liver; Male; Naphthalenes; Pravastatin; Rabbits; Receptors, LDL; RNA, Messenger | 1989 |
Rational therapy of familial hypercholesterolemia.
Topics: Animals; Anticholesteremic Agents; Cholestyramine Resin; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Naphthalenes; Pravastatin; Rabbits; Receptors, LDL | 1989 |
Normalization of LDL receptor function by lymphocytes of patients with heterozygous familial hypercholesterolemia after treatment with plasma cholesterol lowering agents.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Colestipol; Drug Combinations; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, LDL; Lovastatin; Lymphocytes; Receptors, Cell Surface; Receptors, Lipoprotein; Reference Values | 1989 |
[Treatment of essential hypercholesterolemia by normolipidemic drugs in children].
Topics: Adolescent; Child; Child, Preschool; Cholestyramine Resin; Clofibrate; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant; Infant, Newborn; Nicotinic Acids; Sulfur | 1989 |
Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Mevalonic Acid | 1989 |
Gemfibrozil plus cholestyramine in familial hypercholesterolaemia.
Topics: Adult; Cholesterol; Cholestyramine Resin; Drug Evaluation; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Pentanoic Acids; Valerates | 1988 |
Combined treatment with cholestyramine and nicotinic acid in heterozygous familial hypercholesterolaemia: effects on biliary lipid composition.
Topics: Adult; Bile; Bile Acids and Salts; Cholesterol; Cholestyramine Resin; Drug Therapy, Combination; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Niacin | 1986 |
Gemfibrozil in the treatment of resistant familial hypercholesterolaemia and type III hyperlipoproteinaemia.
Topics: Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hypolipidemic Agents; Male; Pentanoic Acids; Triglycerides; Valerates | 1988 |
Drug therapy in children and adolescents with familial hypercholesterolemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant; Male; Niacin | 1988 |
Medical management of hyperlipidemia and the role of probucol.
Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Niacin; Pentanoic Acids; Phenols; Probucol; Risk | 1986 |
Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil.
Topics: Cholestyramine Resin; Chylomicrons; Dietary Fats; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Lipoproteins; Male; Pentanoic Acids; Triglycerides; Valerates; Vitamin A | 1987 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Drug Tolerance; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Probucol; Simvastatin; Triglycerides | 1987 |
Safety and efficacy of long-term diet and diet plus bile acid-binding resin cholesterol-lowering therapy in 73 children heterozygous for familial hypercholesterolemia.
Topics: Adolescent; Behavior; Bile Acids and Salts; Body Height; Body Weight; Child; Cholesterol; Cholestyramine Resin; Colestipol; Drug Evaluation; Evaluation Studies as Topic; Female; Follow-Up Studies; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Polyamines; Sexual Maturation | 1986 |
Liver transplantation for treatment of cardiovascular disease: comparison with medication and plasma exchange in homozygous familial hypercholesterolemia.
Topics: Child; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Coronary Disease; Homozygote; Humans; Hyperlipoproteinemia Type II; Liver Transplantation; Lovastatin; Male; Naphthalenes; Niacin; Plasma Exchange; Skin Diseases; Xanthomatosis | 1987 |
Plasma exchange in a patient with heterozygous familial hypercholesterolaemia resistant to drug therapy.
Topics: Adult; Cholestyramine Resin; Drug Resistance; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Nicotinic Acids; Plasma Exchange | 1987 |
Efficacy of mevinolin as adjuvant therapy for refractory familial hypercholesterolaemia.
Topics: Adult; Aged; Cholesterol; Cholestyramine Resin; Drug Therapy, Combination; Female; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; Ileum; Lovastatin; Male; Middle Aged; Naphthalenes | 1986 |
Comparison of six pharmacologic regimens for hypercholesterolemia.
Topics: Adult; Aged; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Neomycin; Niacin; Retrospective Studies | 1987 |
[Use of cholestyramine by patients with chronic ischemic heart disease].
Topics: Adult; Cholestyramine Resin; Coronary Disease; Female; Humans; Hyperlipoproteinemia Type II; Kallikreins; Kinins; Male; Middle Aged | 1987 |
Effects of probucol on xanthomata regression in familial hypercholesterolemia.
Topics: Achilles Tendon; Adolescent; Adult; Aged; Anticholesteremic Agents; Child; Child, Preschool; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Phenols; Plasmapheresis; Probucol; Xanthomatosis | 1986 |
Long-term effects of bezafibrate and of a bezafibrate and cholestyramine combination on lipids and lipoprotein lipids in type IIa hypercholesterolaemic patients.
Topics: Adult; Bezafibrate; Cholesterol; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Middle Aged | 1986 |
The effect of combined fenofibrate and cholestyramine therapy on low-density lipoprotein kinetics in familial hypercholesterolemia patients.
Topics: Adult; Apolipoproteins; Cholestyramine Resin; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Kinetics; Lipids; Lipoproteins, LDL; Male; Middle Aged; Propionates | 1987 |
The association of LDL receptor activity, LDL cholesterol level, and clinical course in homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cholestyramine Resin; Female; Fibroblasts; Homozygote; Humans; Hyperlipoproteinemia Type II; Lipoproteins, VLDL; Male; Receptors, LDL | 1985 |
Treatment of homozygous familial hypercholesterolaemia: an informative sibship.
Topics: Adolescent; Age Factors; Arteriosclerosis; Cholestyramine Resin; Clofibrate; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Infant; Male; Middle Aged; Niacin | 1985 |
Nonprogression of coronary artery atherosclerosis in homozygous familial hypercholesterolemia after 31 months of repetitive plasma exchange.
Topics: Achilles Tendon; Adult; Angiography; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Coronary Disease; Echocardiography; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Plasma Exchange; Probucol; Xanthomatosis | 1986 |
Sterol synthesis in vitro in freshly isolated blood mononuclear leukocytes from familial hypercholesterolemic patients treated with probucol.
Topics: Cholesterol; Cholestyramine Resin; Female; Humans; Hyperlipoproteinemia Type II; Male; Monocytes; Phenols; Probucol; Sterols | 1985 |
Effect of plasma exchange with and without concomitant drug treatment on lipids and lipoproteins in patients with familial hypercholesterolemia confirmed by tissue culture.
Topics: Adult; Apolipoproteins; Cholestyramine Resin; Combined Modality Therapy; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Nicotinyl Alcohol; Plasma Exchange | 1985 |